170 related articles for article (PubMed ID: 31500103)
1. Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma.
Hori R; Shinohara S; Kojima T; Kagoshima H; Kitamura M; Tateya I; Tamaki H; Kumabe Y; Asato R; Harada H; Kitani Y; Tsujimura T; Honda K; Ichimaru K; Omori K
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500103
[TBL] [Abstract][Full Text] [Related]
2. Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S; Hori R; Shinohara S; Kojima T; Tamaki H; Asato R; Kitamura M; Ichimaru K; Kitani Y; Kumabe Y; Honda K; Tsujimura T; Harada H; Ushiro K; Omori K
Auris Nasus Larynx; 2022 Oct; 49(5):834-844. PubMed ID: 35232636
[TBL] [Abstract][Full Text] [Related]
3. Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer.
Abbas W; Gupta S; Goel V; Rao RR; Pankaj P; Tripathi D; Patil PP; Popli S
South Asian J Cancer; 2021 Apr; 10(2):72-75. PubMed ID: 34568218
[No Abstract] [Full Text] [Related]
4. Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
Ueda Y; Okano S; Enokida T; Fujisawa T; Ito K; Sato M; Tanaka H; Wada A; Tahara M
Oral Oncol; 2022 Jul; 130():105932. PubMed ID: 35636078
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
[TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
Kiyota N; Hasegawa Y; Takahashi S; Yokota T; Yen CJ; Iwae S; Shimizu Y; Hong RL; Goto M; Kang JH; Sum Kenneth Li W; Ferris RL; Gillison M; Namba Y; Monga M; Lynch M; Tahara M
Oral Oncol; 2017 Oct; 73():138-146. PubMed ID: 28939066
[TBL] [Abstract][Full Text] [Related]
8. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
[TBL] [Abstract][Full Text] [Related]
9. Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients.
Matsuki T; Okamoto I; Fushimi C; Takahashi H; Okada T; Kondo T; Sato H; Ito T; Tokashiki K; Tsukahara K; Hanyu K; Masubuchi T; Tada Y; Miura K; Omura G; Sawabe M; Kawakita D; Yamashita T
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33218183
[TBL] [Abstract][Full Text] [Related]
10. Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study.
Vasiliadou I; Breik O; Baker H; Leslie I; Sim VR; Hegarty G; Michaelidou A; Nathan K; Hartley A; Good J; Sanghera P; Fong C; Urbano TG; Lei M; Petkar I; Ferreira MR; Nutting C; Wong KH; Newbold K; Harrington K; Bhide S; Kong A
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808781
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma.
Ueta R; Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Ouchi K; Kasahara Y; Taniguchi S; Yoshida Y; Sasaki K; Shirota H; Takahashi M; Ishioka C
Oncology; 2024; 102(3):252-259. PubMed ID: 37708868
[TBL] [Abstract][Full Text] [Related]
12. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).
Yen CJ; Kiyota N; Hanai N; Takahashi S; Yokota T; Iwae S; Shimizu Y; Hong RL; Goto M; Kang JH; Li WSK; Ferris RL; Gillison M; Endo T; Jayaprakash V; Tahara M
Head Neck; 2020 Oct; 42(10):2852-2862. PubMed ID: 32583557
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study.
Okamoto I; Sato H; Kondo T; Koyama N; Fushimi C; Okada T; Miura K; Matsuki T; Yamashita T; Omura G; Tsukahara K
Acta Otolaryngol; 2019 Oct; 139(10):918-925. PubMed ID: 31460818
[No Abstract] [Full Text] [Related]
14. Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab.
Nishikawa D; Suzuki H; Koide Y; Beppu S; Kadowaki S; Sone M; Hanai N
Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30477171
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
16. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
18. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Taura M; Uchi R; Nakagawa T
Oral Oncol; 2020 Feb; 101():104525. PubMed ID: 31863963
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.
Botticelli A; Mezi S; Pomati G; Sciattella P; Cerbelli B; Roberto M; Mammone G; Cirillo A; Cassano A; Di Dio C; Cortellini A; Pizzuti L; Ronzino G; Salati M; Vici P; Polimeni A; Merlano MC; Nuti M; Marchetti P
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32326034
[TBL] [Abstract][Full Text] [Related]
20. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
